Company intelligence / Profile preview

Chiome Bioscience Inc.

Tokyo (Shibuya-ku), Tokyo Prefecture, Japanchiome.co.jp ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Chiome Bioscience Inc. specializes in developing therapeutic monoclonal antibodies using proprietary platforms such as the ADLib® system. The company focuses on both internal drug discovery and providing development support services to pharmaceutical partners. It has a pipeline targeting novel antigens with an emphasis on oncology/immuno-oncology applications. Recent reports include progress in cancer immunotherapy research.

Therapeutic areas: OtherOncology
Modalities: Monoclonal antibodies (mAbs)Multi-specific antibodiesRecombinant proteins
Industry: Biotech

Drug pipeline

8 assets

cba-1205

7 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with pharmaceutical companies domestically and internationally for lead antibody development and licensing; specific partners not listed by name.

Beyond the preview

Go deeper on Chiome Bioscience Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chiome Bioscience Inc..

Explore the full profile